190 Chapter 8 Placebo Adjunctive rifampicin P-value Sub-phenotype A n=60 n=55 84-day mortality 13 (21.7) 12 (21.8) >0.99 Composite microbiologic failure 1 (1.9) 0 (0) >0.99 Sub-phenotype B n=52 n=55 84-day mortality 0 (0) 8 (14.5) 0.006 Composite microbiologic failure 0 (0) 1 (1.9) >0.99 Sub-phenotype C n=138 n=138 84-day mortality 29 (21.0) 24 (17.4) 0.54 Composite microbiologic failure 11 (8.6) 2 (1.6) 0.02 Sub-phenotype D n=69 n=52 84-day mortality 11 (15.9) 11 (21.2) 0.48 Composite microbiologic failure 6 (8.8) 3 (6.0) 0.73 Sub-phenotype E n=69 n=70 84-day mortality 3 (4.3) 1 (1.4) 0.37 Composite microbiologic failure 3 (4.3) 1 (1.4) 0.62 Supplementary Table 2: Effect of adjunctive rifampicin stratified by sub-phenotype. Treatment outcomes within each sub-phenotype were compared using Fisher’s exact test. Data shown as n (%). Two comparisons were made within each sub-phenotype so the significance level was set at 0·025 (alpha=0·05, n=2). Laboratory information management system search • S. aureus isolated from blood culture specimens • Age ≥18 years • 20/12/2019–23/08/2022 Patients excluded: • Polymicrobial bacteraemia with additional significant organism, n=14 • No electronic records available (transferred to other health board or renal dialysis patient managed entirely as outpatient), n=4 • Growth of S. aureus determined by infection specialist to represent contamination, n=2 • Death within 24h of index blood culture and no active treatment, n=6 Final Edinburgh cohort n=458 n=484 unique patients identified Supplementary Figure 1: Flow diagram for Edinburgh retrospective observational cohort
RkJQdWJsaXNoZXIy MTk4NDMw